GlassScriptPhysician profile
Abdul S Soudan
NPI 1013939198
$9,944.17
in general payments reported to CMS, 2019-2025
47 companies · $636 in 2025
The $636 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,709 · 2020: $995 · 2021: $1,444 · 2022: $2,454 · 2023: $1,585 · 2024: $1,121 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,342.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $2,197.33 | 2019-2025 | Belbuca, Xtampza |
| Spinal Simplicity, LLC | $1,202.41 | 2022-2025 | Ha Minuteman G3-R |
| Abbott Laboratories | $863.26 | 2019-2024 | Proclaim, Eterna, Octrode |
| Nevro Corp. | $779.15 | 2019-2024 | Senza |
| Boston Scientific Corporation | $697.43 | 2019-2025 | Infinion 16, Wavewriter Alpha Prime 16, Intracept |
| Biodelivery Sciences International, INC. | $350.14 | 2019-2021 | |
| Biotronik Nro, INC. | $317.26 | 2023-2024 | Prospera, Biotronik |
| Almatica Pharma LLC | $288.72 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $287.18 | 2019-2022 | |
| Electronic Waveform Lab, INC. | $260.39 | 2019-2024 | |
| Protega Pharmaceutials INC | $256.31 | 2023-2025 | Roxybond |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.23 | 2019-2023 | Relistor |
| Horizon Therapeutics Plc | $182.60 | 2019-2022 | |
| Medtronic, INC. | $160.44 | 2021-2025 | Intellis Adaptivestim, Accurian, Kyphon Express II Kyphopak Tray |
| Assertio Therapeutics, INC. | $146.40 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$12,088.54 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Soudan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.